-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34

Benzinga·05/14/2026 13:11:07
Listen to the news
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $40 to $34.